Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2025-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Tianjian for the year 2024. It details the qualifications, independence, quality management, work plan, and risk management of the auditor. It is not the audit report itself but an assessment of the auditor's performance and compliance with regulatory requirements. The document length is 2806 characters, which is relatively short and consistent with a standalone audit-related report rather than a full annual report or interim report. There is no financial statement data or detailed financial analysis present. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related information about audit quality and compliance, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-27 Chinese
2024年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the year 2024, prepared by Zhejiang Tailin Biotechnology Co., Ltd. It includes financial figures such as balances, amounts occupied, interest, and repayments related to related parties and subsidiaries. The document is short (1276 characters) and primarily tabular financial data related to related party transactions. It does not contain a full financial report, management discussion, or audit opinion. It is not an announcement or a certification but a detailed financial summary of related party fund usage. This type of document typically falls under Regulatory Filings (RNS) as it is a compliance disclosure about related party transactions and fund occupation, which does not fit into other specific categories like Annual Report, Interim Report, or Audit Report. Therefore, the best classification is Regulatory Filings (RNS).
2025-04-27 Chinese
独立董事2024年度述职报告（董明）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director of Zhejiang Tailin Biotechnology Co., Ltd. for the year 2024. It includes the director's attendance at board and shareholder meetings, committee work, communication with auditors, oversight of related party transactions, and other governance activities. The content focuses on the director's duties, governance, and compliance with laws and regulations, rather than financial results or audit opinions. It is not a full annual report, audit report, or financial statement. It is also not a brief announcement or a proxy solicitation. The document fits best into the category of Board/Management Information (MANG), as it reports on changes and activities related to the company's board and senior management roles, specifically the independent director's annual work report.
2025-04-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the fourth board of directors' seventh meeting of Zhejiang Tailin Biotechnology Co., Ltd. It includes approvals of various reports such as the 2024 Annual Report, 2025 Q1 Report, 2024 Board Work Report, 2024 General Manager Work Report, 2024 Profit Distribution Plan, 2024 Financial Statements, 2024 Audit Report, and other governance and financial matters. The document repeatedly states that the full reports are published on the official disclosure website and that these resolutions will be submitted to the 2024 Annual General Meeting for approval. The document itself is a board meeting resolution announcement, not the full reports. It also includes approvals related to capital changes and remuneration plans, but these are part of the board meeting agenda. The document is over 7,000 characters and contains substantive content about the board meeting decisions, but it does not contain the full financial reports or detailed financial data itself. Therefore, it is best classified as Board/Management Information (MANG) because it announces board meeting resolutions and management decisions rather than the full annual or quarterly reports themselves.
2025-04-27 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2022年限制性股票激励计划部分已授予尚未归属的限制性股票作废事项之法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted stocks under a 2022 restricted stock incentive plan of Zhejiang Tailin Biotechnology Co., Ltd. It discusses legal compliance, approvals by the board and supervisory committees, and the rationale for the cancellation of shares due to employee departures and unmet performance targets. The document is a standalone legal opinion related to a stock incentive plan and does not contain financial statements or earnings data. It is not an annual report, earnings release, or management discussion. It is not a regulatory announcement or a report publication announcement. The document fits best under the category of a legal proceedings report or legal opinion related to corporate governance and stock incentive plans. Given the detailed legal nature and focus on compliance and approvals, the most appropriate classification is Legal Proceedings Report (LTR).
2025-04-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhejiang Tailin Biotechnology Co., Ltd. It details the approval of various reports and proposals including the 2024 Annual Report, 2025 Q1 Report, 2024 Supervisory Board Work Report, 2024 Profit Distribution Plan, 2024 Financial Statements, 2024 Audit Report, and other related financial and governance matters. However, the document itself does not contain the full reports or detailed financial data but rather states that the full reports are published on the designated disclosure website (cninfo.com.cn). The document is a formal announcement of the Supervisory Board's meeting resolutions and approvals, not the reports themselves. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of meeting resolutions and approvals related to various reports and proposals, without containing the full reports or substantive financial data within the text.
2025-04-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.